Isosceles Pharmaceuticals Signs Non-Binding Letter of Intent With a Strategic Partner for Phase 1 Development of Its Proprietary Synthetic Cannabidiol Intravenous Product

Isosceles Pharmaceuticals, Inc., a preclinical stage pharmaceutical company ("Isosceles", or the "Company") engaged in the development of synthetic cannabidiol for the treatment of pain has announced the execution of a non-binding letter of intent with a strategic partner for the phase 1 development of the Company's intravenous product, IPI 201. The non-binding letter of intent […]

Read More
Isosceles Pharmaceuticals appoints Herbert Neuman, MD, MBA Chief Medical Officer and adds Thomas Harrison, LH.D as a strategic advisor

Growing Isosceles Pharmaceuticals team pushes to develop novel, non-opioid products to treat acute pain Isosceles Pharmaceuticals welcomed two new team members – Herbert Neuman, MD, MBA, and Thomas L. Harrison LH.D – to their award-winning mission. The early-stage venture launched two years ago, setting out to formulate and commercialize products that effectively and safely treat […]

Read More
Isosceles Pharmaceuticals, Inc. Appoints William D. Humphries as its Chief Executive Officer

Seasoned pharmaceutical executive with more than 30 years of Commercial and Business Strategy experience Isosceles Pharmaceuticals Inc. a biotechnology company dedicated to developing, commercializing, and marketing innovative non-opioid products for the treatment of mild to moderate pain and inflammatory diseases, today announced the appointment of William D. Humphries as its Chief Executive Officer. Mr. Humphries […]

Read More
Tapping Synthetic CBD For Pain Relief

SOURCE: GREATER WILMINGTON BUSINESS JOURNAL BY JENNY CALLISON BIOTECH | ISOSCELES PHARMACEUTICALS INC. BRETT LANIER, PRESIDENT | YEAR FOUNDED: 2019 | EMPLOYEES: 7 (Photo by Terah Wilson) Early-stage venture Isosceles Pharmaceuticals is working on developing non-opioid pain relief alternatives to opium-derived drugs such as Oxycodone. Working with a group of medical doctors and pharmaceutical Ph.D.s, […]

Read More
Isosceles Pharmaceuticals Wins Coastal Entrepreneur Award

Isosceles Pharmaceuticals recently won a 2020 Coastal Entrepreneur Award (CEA) for the Biotechnology category. The industry accolades – presented by the Greater Wilmington Business Journal and The Center for Innovation and Entrepreneurship (CIE) at the University of North Carolina Wilmington – celebrate rising ventures in the Cape Fear region. “Our entire team is honored to […]

Read More
Winners Of Inaugural NC BIONEER Venture Challenge Announced

Isosceles Pharmaceuticals was named the first-place winner of the NC BIONEER Venture Challenge which aims to enhance life sciences and biotechnology business ventures in the region. Article from A Wilmington company developing non-opioid solutions for pain relief is the first-place winner of the inaugural NC BIONEER Venture Challenge, according to an announcement Tuesday. Isosceles […]

Read More
Copyright © 2022 · Isosceles Pharmaceuticals, Inc.